title: Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis.
abstract: To elucidate the role played by interferon-alpha (IFN alpha) in the pathogenesis of autoimmune endocrine disease, we determined the autoantibody status, thyroid function test results, hemoglobin-A1c levels, and clinical symptoms of 58 patients who received IFN alpha for treatment of chronic active type C hepatitis. Each patient was treated for 6 months with a total dose of 391 +/- 140 x 10(6) U (mean +/- SD). Thyroid microsomal and/or thyroglobulin antibodies newly appeared or were increased in titer in 6 patients, 2 of whom developed hypothyroidism during IFN alpha therapy. Neither islet cell antibodies nor insulin-dependent diabetes mellitus developed during IFN alpha therapy, although hemoglobin-A1c levels were increased in 2 patients. One patient became positive for antimitochondrial antibodies, and another patient with preexisting antimitochondrial antibodies also manifested deterioration in liver function test results. Parietal cell antibodies and smooth muscle cell antibodies were the most frequent newly developed antibodies in 7 patients. Adrenal medullary cell antibodies and nuclear antibodies newly developed in 2 and 1 patients, respectively. At least 1 of 8 autoantibodies newly appeared in 19 patients (32.8%) and hypothyroidism developed in 2 patients (3.4%) during IFN alpha therapy. On the other hand, in 19 age- and sex-matched patients who did not receive IFN alpha, no autoantibody appeared, and no autoimmune disease developed during a follow-up period of 3 months. These findings suggest that IFN alpha acts as an immunomodulatory agent, inducing autoantibody production and the development of autoimmune disease in susceptible patients. Special attention should be paid to the development of hypothyroidism during IFN alpha therapy.
authors.affiliation: Second Department of Internal Medicine, Osaka University Medical School, Suita, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Imagawa
authors.forename: N
authors.initials: N
authors.lastname: Itoh
authors.forename: T
authors.initials: T
authors.lastname: Hanafusa
authors.forename: Y
authors.initials: Y
authors.lastname: Oda
authors.forename: M
authors.initials: M
authors.lastname: Waguri
authors.forename: J
authors.initials: J
authors.lastname: Miyagawa
authors.forename: N
authors.initials: N
authors.lastname: Kono
authors.forename: M
authors.initials: M
authors.lastname: Kuwajima
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuzawa
mesh_terms: D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000209:etiology*; D003920:Diabetes Mellitus / Q000209:etiology; D004700:Endocrine System Diseases / Q000209:etiology*; D005260:Female; D006526:Hepatitis C / Q000628:therapy*; D006521:Hepatitis, Chronic / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects*; D007515:Islets of Langerhans / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D013961:Thyroid Gland / Q000276:immunology
chemical_list: D001323:Autoantibodies; D007370:Interferon Type I; D011994:Recombinant Proteins